☆ 4.6 Article

The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation

Nico Gagelmann et al.

Summary: TP53 mutations are associated with poor outcomes in patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Multihit TP53 mutations are associated with worse prognosis, while single-hit TP53 mutations have similar outcomes to non-mutated TP53. This study helps predict survival and relapse risk in these patients.

BLOOD (2023)

Add to Collection

Article Hematology

Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management

Ayalew Tefferi

Summary: Primary myelofibrosis is a stem cell-derived disorder characterized by clonal myeloproliferation, fibrosis, and other symptoms. Diagnosis is made through bone marrow examination and genetic testing. Treatment options mainly involve drug therapy, and new agents are under investigation.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Review Hematology

Genetic basis and molecular profiling in myeloproliferative neoplasms

Damien Luque Paz et al.

Summary: BCR-ABL1-negative MPNs are clonal hematopoietic diseases characterized by excessive production of mature blood cells. The three subtypes include PV, ET, and PMF, diagnosed based on WHO and ICC criteria. Acquired gain-of-function mutations in JAK2, CALR, and MPL are causative events that activate the JAK/STAT signaling pathway. Limiting factors in MPN development include clone expansion, inherited predisposition, additional mutations, and inflammation. Understanding the mutational landscape in individual patients is important for predicting outcomes and choosing optimal therapy.

BLOOD (2023)

Add to Collection

Article Hematology

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber et al.

Summary: In 2016, the WHO, Society for Hematopathology, and European Association for Haematopathology collaborated to update the classification of myeloid neoplasms and acute leukemias, advancing the field of myeloid neoplasms and acute leukemias.

BLOOD (2022)

Add to Collection

Article Education, Scientific Disciplines

Molecular prognostication in Ph-negative MPNs in 2022

Alessandro Maria Vannucchi et al.

Summary: The application of genomic techniques in patients with myeloproliferative neoplasms has changed the diagnostic approach and management, and improved risk stratification and prognostication. Driver mutated genes such as JAK2, MPL, and CALR are associated with clinical characteristics, complications, and survival outcomes. New clinical and cytogenetic/mutation scores have been developed to guide stem cell transplantation and predict transplant-associated risks.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

Add to Collection

Article Hematology

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Eric J. Duncavage et al.

Summary: Myeloid neoplasms and acute leukemias are caused by somatic gene mutations that drive the clonal expansion of hematopoietic cells. Genomic characterization plays a crucial role in diagnosis, risk assessment, and clinical decision making. Conventional cytogenetics has been the main method for genomic testing, but recent advances in sequencing technology allow for more accurate detection of somatic mutations. Whole-genome sequencing shows potential as a replacement for traditional methods in patients with myeloid neoplasms, providing rapid and comprehensive genomic profiling.

BLOOD (2022)

Add to Collection

Article Hematology

Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study

Damien Luque Paz et al.

Summary: This study identified four genomic groups associated with the prognosis of myelofibrosis, with TP53 and high-risk groups showing significant associations with leukemic transformation and death from myelofibrosis. ASXL1 mutations alone were found to have no prognostic value but worsened the prognosis when associated with other high-risk mutations.

BLOOD ADVANCES (2021)

Add to Collection

Review Hematology

2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management

Haris Ali et al.

Summary: The number of patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation is increasing, as it is currently the only curative treatment. However, factors such as indications for HSCT, comorbidities, age, and disease phase need to be considered to address the limitations preventing more patients from undergoing this treatment.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera

Ayalew Tefferi et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Hematology

RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features

Giacomo Coltro et al.

BLOOD ADVANCES (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

Giuseppe G. Loscocco et al.

ONCOTARGETS AND THERAPY (2020)

Add to Collection

Article Oncology

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

B. Kubesova et al.

LEUKEMIA (2018)

Add to Collection

Letter Oncology

MIPSS70+Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

Ayalew Tefferi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

Paola Guglielmelli et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

J. Grinfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients

Ayalew Tefferi et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Oncology

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

A. Stengel et al.

LEUKEMIA (2017)

Add to Collection

Article Medicine, General & Internal

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Elli Papaemmanuil et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

P. Guglielmelli et al.

LEUKEMIA (2014)

Add to Collection

Article Oncology

Mutations and prognosis in primary myelofibrosis

A. M. Vannucchi et al.

LEUKEMIA (2013)

Add to Collection

Article Oncology

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Naseema Gangat et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.